AP32788 patent publishes...and the compound is...
A next-gen pan-EGFR inhibitor, pretty much consistent with my (latest) guess. Emphasis, and unmet need, focuses on Exon 20 mutations.
SUMMARY
[13] Compounds are disclosed herein that are capable of inhibiting mutant EGFR proteins, e.g.,
EGFR having one or more mutations in the exon 20 domain. In some embodiments, compounds
disclosed herein selectively inhibit mutant EGFR, such as EGFR having one or more exon 20 mutations,
over wild-type EGFR. In other embodiments, the compounds selectively inhibit mutant EGFR, such as
EGFR having an exon 20 point mutation together with an exon 19 or exon 21 mutation. Such inhibitors
can be effective in ameliorating diseases and disorders associated with mutant EGFR activity.
[14] Compounds disclosed herein are capable of inhibiting mutant HER2, e.g., HER2 having one or
more mutations in the exon 20 domain. In some embodiments, the disclosed compounds selectively
inhibit mutant HER2, such as HER2 having one or more exon 20 mutations, over wild-type EGFR. Such
inhibitors can be effective in ameliorating diseases and disorders associated with mutant HER2 activity.
patentscope.wipo.int
I will post more later...
|
